Egypt Multiple Myeloma Research Review Issue 3

In this issue:
  -  Adjusted vs. continuous Rd for elderly, intermediate-fit, newly diagnosed MM
  -  Novel combinations for lenalidomide-refractory MM
  -  PCD for relapsed/refractory MM
  -  Isatuximab-carfilzomib-dexamethasone in relapsed MM
  -  Temporal changes of MM care costs in Denmark and Sweden
  -  Subcutaneous daratumumab formulation for relapsed/refractory MM
  -  MRD dynamics with continuous lenalidomide maintenance for MM
  -  TOURMALINE-MM1 final OS analysis
  -  Daratumumab-pomalidomide-dexamethasone in previously treated MM
  -  Weekly carfilzomib-lenalidomide-dexamethasone-daratumumab in newly diagnosed MM

Download PDF Subscribe